Olema Pharmaceuticals (NASDAQ:OLMA) Given New $38.00 Price Target at Guggenheim

Olema Pharmaceuticals (NASDAQ:OLMA) had its price objective trimmed by Guggenheim from $40.00 to $38.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also weighed in on the stock. Stifel Nicolaus began coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price objective on the stock. TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright lowered their target price on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, The Goldman Sachs Group raised their price target on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $43.22.

Olema Pharmaceuticals Trading Down 9.3%

Shares of Olema Pharmaceuticals stock opened at $15.06 on Tuesday. The stock has a market capitalization of $1.03 billion, a PE ratio of -8.10 and a beta of 1.92. Olema Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $36.26. The stock has a 50 day moving average price of $23.81 and a two-hundred day moving average price of $18.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, March 16th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. As a group, equities analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Naseem Zojwalla sold 99,509 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total value of $2,752,418.94. Following the completion of the sale, the insider directly owned 4,488 shares of the company’s stock, valued at approximately $124,138.08. This represents a 95.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Shane William Charles Kovacs sold 100,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the transaction, the insider owned 139,727 shares in the company, valued at approximately $4,014,356.71. This trade represents a 41.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 805,501 shares of company stock worth $23,003,832 in the last three months. 16.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OLMA. Ameritas Investment Partners Inc. increased its stake in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after buying an additional 2,168 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares during the last quarter. Torren Management LLC purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $44,000. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $53,000. Finally, American Century Companies Inc. bought a new position in shares of Olema Pharmaceuticals in the second quarter valued at approximately $54,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Company update: Olema reiterated clinical progress and strong cash position — OPERA‑01 pivotal top‑line readout still on track for fall 2026, OPERA‑02 enrollment advanced, a Phase 1b/2 combo study with Pfizer’s atirmociclib was initiated, OP‑3136 enrollment continues with initial data expected in Q2 2026, and the company ended 2025 with $505.4M in cash after raising $218.5M in a follow‑on offering. These items materially de‑risk near‑term financing and support runway into late‑stage catalysts. Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Earnings beat (small): Olema reported Q4 EPS of ($0.50), narrowly beating consensus of ($0.51). The modest beat appears to have supported a short‑term rally yesterday. View Press Release
• Positive Sentiment: Bullish analyst action: Citigroup raised its price target from $60 to $62 and maintained a Buy rating, implying substantial upside vs. current levels — a supportive read for longer‑term holders. Benzinga
• Neutral Sentiment: Analyst revision with mixed tone: Guggenheim trimmed its price target from $40 to $38 but kept a Buy rating, a mild pullback in expectations that still signals conviction in the thesis. Benzinga
• Negative Sentiment: Near‑term selling pressure: Shares fell today after a notable intraday jump yesterday (around a 9% move) following the earnings surprise — the pullback looks consistent with profit‑taking after the rally and the mixed analyst actions (Guggenheim’s lower PT). The combination of short‑term traders taking gains and differing analyst targets is likely weighing on the stock despite operational positives. Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.